Harte Hanks, Inc. (HHS)
Live price chart, market sentiment, and community perspectives for Harte Hanks, Inc. (NASDAQ: HHS).
Live price chart, market sentiment, and community perspectives for Harte Hanks, Inc. (NASDAQ: HHS).
On our desk, the Star Equity acquisition announcement at $5.00 per share completely overshadows the deteriorating first-half financials for Harte Hanks. With HHS trading around $2.50 prior to the August 14, 2026 Form 8-K filing, the deal represents an approximate 100% premium. We are evaluating the 50% cash and 50% Star Equity 10% preferred stock structure closely, mapping out potential spread capture strategies while remaining mindful of broader market caution reflected in the 17/100 tape score.
Looking at the Q2 2026 10-Q filing data, Harte Hanks was struggling operationally before the merger agreement. Quarterly revenue dropped to $37.98 million, and net losses widened significantly to $5.00 million with basic and diluted EPS at $(0.67). For the first half of 2026, revenue slid 6.2% to $75.25 million with an operating loss of $5.26 million. Cash and restricted cash sat tight at $5.19 million. Fundamentally, finding a buyer at $5.00 per share came just in time given the burn rate.
Monitoring StockTwits and Twitter social sentiment tracks a surge in message volume and engagement velocity following the definitive merger announcement. Retail chatter has shifted quickly from the ongoing Project Elevate restructuring—which had accumulated $10 million in charges through March 2026—to the mechanics of the Star Equity transaction terms and the board's unanimous recommendation to vote in favor.
From our quantitative trading perspective, the massive gap between the pre-announcement trading price of $2.50 and the agreed $5.00 buyout price creates a classic merger arbitrage scenario. However, because the consideration includes Star Equity 10% preferred stock alongside cash, we have to price in the volatility and liquidity profile of Star Equity's securities (NASDAQ: STRR / STRRP) rather than treating this as a clean, all-cash takeout.
As a risk manager reviewing the quantitative setups, the O'Shaughnessy factor stack scores a modest 53/100, and overall evidence scoring sits at a defensive 37 caution level. Even though the merger agreement provides a clear ceiling and floor tied to the $5.00 acquisition price, our pre-merger risk models flagged heavy pressure in the weekly tape and persistent revenue drops across Fulfillment and Logistics and Revenue Solutions observed back in Q1 2026.
Explore plasma cleansing, somatic organ swaps, and BCI.